Skip to main content

Table 2 Transplant outcomes in the intervention and control groups

From: ICT-based adherence monitoring in kidney transplant recipients: a randomized controlled trial

  Intervention (n = 51) Control (n = 54) p value
Drug levels
 TAC trough level, ng/mL 5.3 ± 1.2 5.0 ± 1.2 0.282
 TAC CVa 23.9 ± 13.5 25.1 ± 11.4 0.645
 MPA trough level, μg/mL 2.8 ± 1.6 2.6 ± 1.3 0.600
 MPA CVa 37.9 ± 17.3 38.9 ± 19.4 0.783
eGFR
 4 weeks 67.8 ± 18.2 71.4 ± 21.8 0.365
 8 weeks 67.9 ± 19.7 71.3 ± 19.2 0.373
 12 weeks 66.7 ± 19.4 71.3 ± 21.6 0.262
 16 weeks 67.6 ± 17.4 72.4 ± 21.9 0.213
 20 weeks 66.3 ± 18.0 71.6 ± 21.8 0.182
 24 weeks 65.2 ± 18.9 70.2 ± 21.0 0.203
Number of events, n (%)
 De novo anti-HLA antibodies 3 (5.9) 8 (14.8) 0.135
 BK viremia 1 (2.0) 1 (1.9) 1.000
 BPAR  
 DCGL  
  1. Values are shown as mean ± standard deviation or number (%)
  2. BPAR Biopsy-proven acute rejection, CV Coefficient of variation, DCGL Death-censored graft loss, eGFR estimated glomerular filtration rate, HLA Human leukocyte antigen, MPA Mycophenolic acid, TAC Tacrolimus
  3. aCV = (standard deviation/mean) × 100%